Skip to main content
Erschienen in: Heart and Vessels 4/2017

22.08.2016 | Original Article

Impact of BNP level and peak VO2 on future heart failure events: comparison between sinus rhythm and atrial fibrillation

verfasst von: Yuko Kato, Shinya Suzuki, Tokuhisa Uejima, Hiroaki Semba, Hiroto Kano, Shunsuke Matsuno, Hideaki Takai, Takayuki Otsuka, Yuji Oikawa, Kazuyuki Nagashima, Hajime Kirigaya, Koichi Sagara, Takashi Kunihara, Junji Yajima, Hitoshi Sawada, Tadanori Aizawa, Takeshi Yamashita

Erschienen in: Heart and Vessels | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to examine the discrete impacts of peak oxygen consumption (VO2) and brain natriuretic peptide (BNP) levels on future heart failure (HF) events in sinus rhythm (SR) and atrial fibrillation (AF). A total of 1447 patients who underwent symptom-limited cardiopulmonary exercise testing and whose BNP values were determined simultaneously were analysed (SR, N = 1151 and AF, N = 296). HF events were defined as HF hospitalization or HF death. Over a mean follow-up period of 1472 days, 140 HF events were observed. A high BNP value (dichotomized by median value) was independently associated with HF events in SR (HR 8.08; 95 % CI 4.02–16.26; p < 0.0001), but not in AF patients (HR 1.97; 95 % CI 0.91–4.28; p = 0.087) with a significant interaction between the rhythms. By contrast, low-peak VO2 was independently associated with HF events in both rhythms (AF; HR 5.81; 95 % CI 1.75–19.30; p = 0.004, SR; HR 2.04; 95 % CI 1.19–3.49; p = 0.009), with a marginal interaction between them. In bivariate Cox models, low-peak VO2 had much stronger predictive power for HF events than high-BNP in AF, whereas high-BNP was more powerful than low-peak VO2 in SR. The prognostic value of BNP and peak VO2 for future HF events seemed to be different between SR and AF.
Literatur
1.
Zurück zum Zitat Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, Tsang TS (2007) Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol 49:986–992CrossRefPubMed Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, Tsang TS (2007) Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol 49:986–992CrossRefPubMed
2.
Zurück zum Zitat Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, Yusuf S, Investigators R-L (2013) Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 128:2192–2201CrossRefPubMed Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, Yusuf S, Investigators R-L (2013) Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 128:2192–2201CrossRefPubMed
3.
Zurück zum Zitat Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D’Agostino RB, Murabito JM, Kannel WB, Benjamin EJ (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107:2920–2925CrossRefPubMed Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D’Agostino RB, Murabito JM, Kannel WB, Benjamin EJ (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107:2920–2925CrossRefPubMed
4.
Zurück zum Zitat Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, Oikawa Y, Yajima J, Koike A, Nagashima K, Kirigaya H, Sawada H, Aizawa T, Yamashita T (2012) A new scoring system for evaluating the risk of heart failure events in Japanese patients with atrial fibrillation. Am J Cardiol 110:678–682CrossRefPubMed Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, Oikawa Y, Yajima J, Koike A, Nagashima K, Kirigaya H, Sawada H, Aizawa T, Yamashita T (2012) A new scoring system for evaluating the risk of heart failure events in Japanese patients with atrial fibrillation. Am J Cardiol 110:678–682CrossRefPubMed
5.
Zurück zum Zitat de Groote P, Dagorn J, Soudan B, Lamblin N, McFadden E, Bauters C (2004) B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 43:1584–1589CrossRefPubMed de Groote P, Dagorn J, Soudan B, Lamblin N, McFadden E, Bauters C (2004) B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 43:1584–1589CrossRefPubMed
6.
Zurück zum Zitat Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR (1991) Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83:778–786CrossRefPubMed Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR (1991) Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83:778–786CrossRefPubMed
7.
Zurück zum Zitat Kubozono T, Itoh H, Oikawa K, Tajima A, Maeda T, Aizawa T, Iinuma H, Tokuda Y, Ohashi Y, Fu LT (2008) Peak VO(2) is more potent than B-type natriuretic peptide as a prognostic parameter in cardiac patients. Circ J 72:575–581CrossRefPubMed Kubozono T, Itoh H, Oikawa K, Tajima A, Maeda T, Aizawa T, Iinuma H, Tokuda Y, Ohashi Y, Fu LT (2008) Peak VO(2) is more potent than B-type natriuretic peptide as a prognostic parameter in cardiac patients. Circ J 72:575–581CrossRefPubMed
8.
Zurück zum Zitat Magri D, Agostoni P, Corra U, Passino C, Scrutinio D, Perrone-Filardi P, Correale M, Cattadori G, Metra M, Girola D, Piepoli MF, Iorio A, Emdin M, Raimondo R, Re F, Cicoira M, Belardinelli R, Guazzi M, Limongelli G, Clemenza F, Parati G, Frigerio M, Casenghi M, Scardovi AB, Ferraironi A, Di Lenarda A, Bussotti M, Apostolo A, Paolillo S, La Gioia R, Gargiulo P, Palermo P, Mina C, Farina S, Battaia E, Maruotti A, Pacileo G, Contini M, Oliva F, Ricci R, Sinagra G, Metabolic Exercise test data combined with C, Kidney Indexes Score Research G (2015) Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. Eur J Prev Cardiol 22:1046–1055CrossRefPubMed Magri D, Agostoni P, Corra U, Passino C, Scrutinio D, Perrone-Filardi P, Correale M, Cattadori G, Metra M, Girola D, Piepoli MF, Iorio A, Emdin M, Raimondo R, Re F, Cicoira M, Belardinelli R, Guazzi M, Limongelli G, Clemenza F, Parati G, Frigerio M, Casenghi M, Scardovi AB, Ferraironi A, Di Lenarda A, Bussotti M, Apostolo A, Paolillo S, La Gioia R, Gargiulo P, Palermo P, Mina C, Farina S, Battaia E, Maruotti A, Pacileo G, Contini M, Oliva F, Ricci R, Sinagra G, Metabolic Exercise test data combined with C, Kidney Indexes Score Research G (2015) Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. Eur J Prev Cardiol 22:1046–1055CrossRefPubMed
9.
Zurück zum Zitat Kato Y, Suzuki S, Kano H, Semba H, Matsuno S, Takai H, Otsuka T, Uejima T, Oikawa Y, Nagashima K, Kirigaya H, Sagara K, Kunihara T, Yajima J, Sawada H, Aizawa T, Yamashita T (2015) Prognostic significance of exercise capacity and resting heart rate: comparison between atrial fibrillation and sinus rhythm. Int J Cardiol 203:561–563CrossRefPubMed Kato Y, Suzuki S, Kano H, Semba H, Matsuno S, Takai H, Otsuka T, Uejima T, Oikawa Y, Nagashima K, Kirigaya H, Sagara K, Kunihara T, Yajima J, Sawada H, Aizawa T, Yamashita T (2015) Prognostic significance of exercise capacity and resting heart rate: comparison between atrial fibrillation and sinus rhythm. Int J Cardiol 203:561–563CrossRefPubMed
10.
Zurück zum Zitat Suzuki S, Yamashita T, Ohtsuka T, Sagara K, Uejima T, Oikawa Y, Yajima J, Koike A, Nagashima K, Kirigaya H, Ogasawara K, Sawada H, Aizawa T (2008) Prevalence and prognosis of patients with atrial fibrillation in Japan: a prospective cohort of Shinken Database 2004. Circ J 72:914–920CrossRefPubMed Suzuki S, Yamashita T, Ohtsuka T, Sagara K, Uejima T, Oikawa Y, Yajima J, Koike A, Nagashima K, Kirigaya H, Ogasawara K, Sawada H, Aizawa T (2008) Prevalence and prognosis of patients with atrial fibrillation in Japan: a prospective cohort of Shinken Database 2004. Circ J 72:914–920CrossRefPubMed
11.
Zurück zum Zitat Japnese Society of Nephrology (2013) Evidence-based clinical practice guideline for CKD (Japanese). Tokyo Igaku, Tokyo, Japan Japnese Society of Nephrology (2013) Evidence-based clinical practice guideline for CKD (Japanese). Tokyo Igaku, Tokyo, Japan
12.
Zurück zum Zitat Nakamura M, Koeda Y, Tanaka F, Onoda T, Itai K, Ohsawa M, Tanno K, Sakata K, Omama S, Ishibashi Y, Makita S, Ohta M, Ogasawara K, Komatsu T, Okayama A (2013) Plasma B-type natriuretic peptide as a predictor of cardiovascular events in subjects with atrial fibrillation: a community-based study. PLoS One 8:e81243CrossRefPubMedPubMedCentral Nakamura M, Koeda Y, Tanaka F, Onoda T, Itai K, Ohsawa M, Tanno K, Sakata K, Omama S, Ishibashi Y, Makita S, Ohta M, Ogasawara K, Komatsu T, Okayama A (2013) Plasma B-type natriuretic peptide as a predictor of cardiovascular events in subjects with atrial fibrillation: a community-based study. PLoS One 8:e81243CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Silvet H, Young-Xu Y, Walleigh D, Ravid S (2003) Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 92:1124–1127CrossRefPubMed Silvet H, Young-Xu Y, Walleigh D, Ravid S (2003) Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 92:1124–1127CrossRefPubMed
14.
Zurück zum Zitat Don-Wauchope AC, McKelvie RS (2015) Evidence based application of BNP/NT-proBNP testing in heart failure. Clin Biochem 48:236–246CrossRefPubMed Don-Wauchope AC, McKelvie RS (2015) Evidence based application of BNP/NT-proBNP testing in heart failure. Clin Biochem 48:236–246CrossRefPubMed
15.
Zurück zum Zitat Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S, Wallentin L (2012) Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation 125:1605–1616CrossRefPubMed Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S, Wallentin L (2012) Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation 125:1605–1616CrossRefPubMed
16.
Zurück zum Zitat Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB (2013) N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol 61:2274–2284CrossRefPubMed Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB (2013) N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol 61:2274–2284CrossRefPubMed
17.
Zurück zum Zitat Sadanaga T, Kohsaka S, Mitamura H, Ogawa S (2011) Elevated B-type natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation. Heart Vessels 26:530–535CrossRefPubMed Sadanaga T, Kohsaka S, Mitamura H, Ogawa S (2011) Elevated B-type natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation. Heart Vessels 26:530–535CrossRefPubMed
18.
Zurück zum Zitat Richards M, Di Somma S, Mueller C, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Clopton P, Filippatos GS, Anand I, Ng L, Daniels LB, Neath SX, Shah K, Christenson R, Hartmann O, Anker SD, Maisel A (2013) Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). JACC Heart Fail 1:192–199CrossRefPubMed Richards M, Di Somma S, Mueller C, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Clopton P, Filippatos GS, Anand I, Ng L, Daniels LB, Neath SX, Shah K, Christenson R, Hartmann O, Anker SD, Maisel A (2013) Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). JACC Heart Fail 1:192–199CrossRefPubMed
19.
Zurück zum Zitat Sitar Taut AV, Pop D, Zdrenghea DT (2015) NT-proBNP values in elderly heart failure patients with atrial fibrillation and diabetes. J Diabetes Complications 29:1119–1123CrossRefPubMed Sitar Taut AV, Pop D, Zdrenghea DT (2015) NT-proBNP values in elderly heart failure patients with atrial fibrillation and diabetes. J Diabetes Complications 29:1119–1123CrossRefPubMed
20.
Zurück zum Zitat Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr (1988) Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 62:191–195CrossRefPubMed Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr (1988) Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 62:191–195CrossRefPubMed
21.
Zurück zum Zitat Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A (1997) Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96:1180–1184CrossRefPubMed Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A (1997) Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96:1180–1184CrossRefPubMed
22.
Zurück zum Zitat Wozakowska-Kaplon B (2004) Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation. Am J Cardiol 93:1555–1558CrossRefPubMed Wozakowska-Kaplon B (2004) Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation. Am J Cardiol 93:1555–1558CrossRefPubMed
23.
Zurück zum Zitat Vinch CS, Rashkin J, Logsetty G, Tighe DA, Hill JC, Meyer TE, Rosenthal LS, Aurigemma GP (2004) Brain natriuretic peptide levels fall rapidly after cardioversion of atrial fibrillation to sinus rhythm. Cardiology 102:188–193CrossRefPubMed Vinch CS, Rashkin J, Logsetty G, Tighe DA, Hill JC, Meyer TE, Rosenthal LS, Aurigemma GP (2004) Brain natriuretic peptide levels fall rapidly after cardioversion of atrial fibrillation to sinus rhythm. Cardiology 102:188–193CrossRefPubMed
Metadaten
Titel
Impact of BNP level and peak VO2 on future heart failure events: comparison between sinus rhythm and atrial fibrillation
verfasst von
Yuko Kato
Shinya Suzuki
Tokuhisa Uejima
Hiroaki Semba
Hiroto Kano
Shunsuke Matsuno
Hideaki Takai
Takayuki Otsuka
Yuji Oikawa
Kazuyuki Nagashima
Hajime Kirigaya
Koichi Sagara
Takashi Kunihara
Junji Yajima
Hitoshi Sawada
Tadanori Aizawa
Takeshi Yamashita
Publikationsdatum
22.08.2016
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 4/2017
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-016-0887-x

Weitere Artikel der Ausgabe 4/2017

Heart and Vessels 4/2017 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.